Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Open accessThe DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index.
Abstract
Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma 1,2, with one study reporting data in cisplatin-ineligible patients who received anti-PD-L1 monotherapy 2. The study reported that patients with bulky tumors, a known high-risk feature defined as greater than clinical T2 disease, had fewer responses, with pathological complete response rate of 17%2. Here we report on the first pilot combination neoadjuvant trial ( NCT02812420 ) with anti-PD-L1 (durvalumab) plus anti-CTLA-4 (tremelimumab) in cisplatin-ineligible patients, with all tumors identified as having high-risk features (n = 28). High-risk features were defined by bulky tumors, variant histology, lymphovascular invasion, hydronephrosis and/or high-grade upper tract disease 3-5. The primary endpoint was safety and we observed 6 of 28 patients (21%) with grade ≥3 immune-related adverse events, consisting of asymptomatic laboratory abnormalities (n = 4), hepatitis and colitis (n = 2). We also observed pathological complete response of 37.5% and downstaging to pT1 or less in 58% of patients who completed surgery (n = 24). In summary, we provide initial safety, efficacy and biomarker data with neoadjuvant combination anti-PD-L1 plus anti-CTLA-4, which warrants further development for patients with localized urothelial carcinoma, especially cisplatin-ineligible patients with high-risk features who do not currently have an established standard-of-care neoadjuvant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“whereas increased frequency of ICOS + CD4 T cells in tumor tissues, possibly in the context of tertiary lymphoid structures, tends to correlate with improved clinical outcomes with ICT (21).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [21]
In the citing paper
“The trial also led to the first combination ICT neoadjuvant trial with anti-CTLA4 plus anti-PD-L1 in patients with bladder cancer, which demonstrated clinical responses and correlation of TLS with responses (21).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Research works printed but not linked: 1
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer, Vol. 2019 (NCCN, 2019).
Cited by
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
Meylan, M., Petitprez, F., Becht, E., Bougoüin, A., Pupier, G., Calvez, A., Giglioli, I., Verkarre, V., Lacroix, G., Verneau, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.02.001 · Cited by 831
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationFridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Metadata
- Authors
- Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., Shah, A. Y., Msaouel, P., Corn, P., Wang, J., Papadopoulos, J. N., Yadav, S. S., Blando, J. M., Duan, F., Basu, S., Liu, W., Shen, Y., Zhang, Y., Macaluso, M. D., Wang, Y., Chen, J., Zhang, J., Futreal, A., Dinney, C., Allison, J. P., Goswami, S., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Gao, Jianjun
- Sharma, Padmanee
- ORCID
- Gao, Jianjun
- Navai, Neema
- Alhalabi, Omar
- Siefker-Radtke, Arlene
- Campbell, Matthew T.
- Tidwell, Rebecca Slack
- Guo, Charles C.
- Kamat, Ashish M.
- Matin, Surena F.
- Araujo, John C.
- Shah, Amishi Y.
- Msaouel, Pavlos
- Corn, Paul
- Wang, Jianbo
- Yadav, Shalini S.
- Blando, Jorge M.
- Duan, Fei
- Basu, Sreyashi
- Liu, Wenbin
- Shen, Yu
- Zhang, Yuwei
- Macaluso, Marc Daniel
- Wang, Ying
- Zhang, Jianhua
- Futreal, Andrew
- Dinney, Colin
- Allison, James P.
- Goswami, Sangeeta
- Sharma, Padmanee
- Venue
- Nature Medicine
- Published
- 2020-10-12
- Volume
- 26
- Issue
- 12
- Pages
- 1845-1851
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9768836
- OpenAlex
- W3092302767
- Cited by
- 318
- References
- 62
- Citations by year
- 2026: 26 · 2025: 47 · 2024: 56 · 2023: 61 · 2022: 72 · 2021: 47 · 2020: 9
- FWCI
- 44.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- urothelial carcinoma, bladder cancer, neoadjuvant immunotherapy, PD-L1 blockade, CTLA-4 blockade, durvalumab, tremelimumab, cisplatin-ineligible patients, high-risk features, pathological complete response, tumor downstaging, immune-related adverse events, predictive biomarkers, immune checkpoint inhibitors
- MeSH terms
- Antineoplastic Agents, Immunological, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Cisplatin, Female, Humans, Male, Middle Aged, Neoplasm Staging, Risk Factors, Urothelium, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. https://app.cochat.ai/papers/10.1038/s41591-020-1086-y
- The paper
- Gao, J., Navai, N., Alhalabi, O., Siefker-Radtke, A., Campbell, M. T., Tidwell, R. S., Guo, C. C., Kamat, A. M., Matin, S. F., Araujo, J. C., Shah, A. Y., Msaouel, P., Corn, P., Wang, J., Papadopoulos, J. N., Yadav, S. S., Blando, J. M., Duan, F., Basu, S., . . . Sharma, P. (2020). Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine. https://doi.org/10.1038/s41591-020-1086-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.